Personalized metabolic & immunomodulatory care in Istanbul
Stem cell therapy for diabetes in Istanbul
Led by Uzm. Dr. Cihan Bolat, our medical team evaluates your diabetes type, HbA1c and C-peptide profile, and medical history to design an individualized Wharton's jelly MSC and exosome protocol aimed at modulating metabolic inflammation and supporting pancreatic and vascular health.
Understanding diabetes and our regenerative approach
Diabetes mellitus — whether autoimmune Type 1, metabolic Type 2, or latent autoimmune diabetes in adults (LADA) — subjects the body's insulin-producing pancreatic beta cells and microvascular networks to relentless biological stress. In Type 1 diabetes, autoreactive T lymphocytes infiltrate pancreatic islets and attack beta cells; in Type 2 diabetes, chronic systemic inflammation in liver, muscle, and adipose tissue blocks intracellular insulin receptor signaling, forcing beta cells to overwork until they suffer oxidative and endoplasmic reticulum exhaustion. Across both types, glycemic fluctuations and inflammation damage small blood vessels supplying peripheral nerves, kidneys, and systemic circulation.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are investigated to address these core immune, islet, and metabolic pathways simultaneously. Inside the body, WJ-MSCs act as potent immunomodulators that calm autoreactive T-cell insulitis, expand protective regulatory T cells (Tregs), and shift pro-inflammatory M1 macrophages in metabolic tissues toward reparative, insulin-sensitizing M2 phenotypes. At the same time, WJ-MSCs and their nanoscale exosomes release trophic growth factors — including IGF-1, HGF, VEGF, and PDX-1-supportive paracrine signals — along with regulatory microRNAs that help shield residual pancreatic beta cells from apoptosis, nourish the dense capillary bed inside pancreatic islets, improve GLUT4 insulin-signaling sensitivity in skeletal muscle and liver cells, and repair microvascular endothelium.
At our clinic in Istanbul, led by Uzm. Dr. Cihan Bolat, our medical team evaluates your diabetes subtype, HbA1c, fasting and stimulated C-peptide levels, kidney and liver panels, and medication history to design a personalized protocol. By combining intravenous WJ-MSC and exosome infusions with targeted intramuscular administration where indicated alongside your ongoing endocrinologist care, our protocols aim to support steadier daily glycemic control, preservation of endogenous beta-cell function, improved peripheral insulin sensitivity, and healthier microvascular circulation.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
What happens inside the body in diabetes — and how biologics help repair and protect
Four core biological processes affect pancreatic islets, peripheral metabolic tissues, and blood vessels in diabetes. Understanding each mechanism illustrates how Wharton's jelly MSCs and exosomes interact with these tissues to support cellular balance.
Therapeutic objectives of our protocol
Our regenerative protocols in Istanbul are designed to support your metabolic and immune microenvironment while you continue your prescribed insulin or glucose-lowering medications under the supervision of your home endocrinologist.
Modulating autoimmune T-cell activity and supporting regulatory T-cell (Treg) balance in inflammatory islet environments
Insulin-producing beta cells within the islets of Langerhans have remarkably low levels of natural antioxidant enzymes, making them highly vulnerable to pro-inflammatory cytokines (IL-1beta, TNF-alpha, IFN-gamma), glucotoxicity, and endoplasmic reticulum protein-folding exhaustion.
Wharton's jelly MSCs and their exosomes release cytoprotective factors (including IGF-1, HGF, VEGF, and antioxidant enzymes) alongside anti-apoptotic microRNAs that help calm intra-islet oxidative stress, nourish islet capillaries, and support the survival and insulin-secreting capacity of residual beta cells.
02
Autoimmune T-cell insulitis & regulatory T-cell imbalance in Type 1 diabetes
In autoimmune Type 1 diabetes and LADA, autoreactive CD4+ and CD8+ T lymphocytes infiltrate pancreatic islets and selectively target beta cells, while endogenous regulatory T-cell (Treg) checkpoints fail to restrain the immune attack.
Intravenously administered WJ-MSCs interact with the immune system to suppress autoreactive T-cell proliferation, inhibit dendritic cell maturation, and expand protective FoxP3+ regulatory T cells — helping quiet islet inflammation and shield remaining beta-cell reserve.
03
Chronic systemic inflammation & peripheral insulin resistance in Type 2 diabetes
In Type 2 diabetes, pro-inflammatory M1 macrophages accumulate in adipose tissue, liver, and skeletal muscle, secreting cytokines that block intracellular IRS-1/PI3K/Akt insulin receptor signaling and impair GLUT4 glucose uptake into cells.
WJ-MSCs and their exosomes reprogram pro-inflammatory M1 macrophages into anti-inflammatory M2 phenotypes and deliver insulin-sensitizing vesicular signals to hepatic and muscle cells, helping restore peripheral glucose uptake and easing the secretory workload on pancreatic beta cells.
Chronic hyperglycemia and advanced glycation end-products damage the endothelial lining of small blood vessels, reducing capillary blood flow to peripheral nerves (diabetic neuropathy), renal glomeruli (nephropathy), and systemic tissues.
Through pro-angiogenic VEGF, angiopoietins, and endothelial-protective exosomes, our protocols support microvascular endothelial repair, healthier capillary perfusion, and neurotrophic support for stressed peripheral nerve fibers.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Biological rationale
Protecting residual beta cells and resolving chronic metabolic inflammation
Research in both Type 1 and Type 2 diabetes shows that pancreatic beta-cell decline and peripheral insulin resistance are heavily driven by local islet inflammation (insulitis), oxidative stress, and pro-inflammatory M1 macrophage activation in metabolic organs. Many patients retain a population of stressed, dysfunctional beta cells that are metabolically silenced rather than permanently destroyed, as reflected by measurable C-peptide levels. By calming autoimmune and metabolic cytokine storms, restoring capillary trophic support within pancreatic islets, and improving peripheral insulin receptor signaling, regenerative therapy aims to protect remaining beta-cell reserve and reduce systemic metabolic strain.
WJ-MSCs & exosomes
Immunomodulation, M1-to-M2 macrophage polarization, and vesicular islet support
Wharton's jelly-derived MSCs and their purified exosomes work through complementary cellular and vesicular pathways to support metabolic repair. Live WJ-MSCs modulate systemic immunity by expanding regulatory T cells (Tregs) to quiet autoimmune islet attack in Type 1 diabetes, while converting inflammatory M1 macrophages into reparative M2 macrophages to restore insulin sensitivity in Type 2 diabetes. Simultaneously, nanoscale WJ-MSC exosomes circulate through the dense microvasculature of the pancreas, liver, skeletal muscle, and peripheral nerves — delivering anti-apoptotic microRNAs and growth factors (IGF-1, HGF, VEGF) that protect beta cells from oxidative stress and support microvascular endothelial repair.
Individualized protocol
Tailored to your diabetes subtype, C-peptide reserve, and endocrine profile
We do not perform surgical portal-vein donor islet transplantation requiring lifelong immunosuppression. Instead, our medical team evaluates your specific diabetes diagnosis, residual C-peptide production, HbA1c trajectory, and renal and vascular markers to design a personalized non-surgical protocol. Depending on your clinical picture, we combine intravenous WJ-MSC and exosome infusions with intramuscular depot administration, while you continue your prescribed insulin or glucose-lowering medications under the guidance of your home endocrinologist.
Our treatment approach & administration routes
Our four-part protocol approach for diabetes
Based on our medical team's evaluation of your endocrine records and lab panels, we combine targeted biological administration routes using GMP-certified Wharton's jelly MSCs and exosomes.
01
Intravenous Wharton's Jelly MSC Infusion
Systemic intravenous infusion of fresh, GMP-certified Wharton's jelly-derived MSCs targets systemic inflammatory cytokines, encourages M1-to-M2 macrophage polarization across liver, adipose, and muscle tissues, and expands regulatory T cells to calm autoimmune and metabolic inflammation.
Role in your protocolForms the primary systemic immunomodulatory and trophic foundation of your diabetes protocol.
02
Intravenous WJ-MSC Exosome Administration
Wharton's jelly MSC-derived exosomes deliver nanoscale extracellular vesicles enriched with regulatory microRNAs, IGF-1, HGF, and VEGF. Because exosomes pass freely through capillary beds without pulmonary trapping, they reach the pancreatic islet microvasculature and peripheral insulin-sensitive organs to support beta-cell protection, endothelial repair, and intracellular insulin signaling.
Role in your protocolComplements cellular infusion with immediate, systemic vesicular signaling across pancreatic, metabolic, and microvascular beds.
03
Intramuscular Administration
Where included in your individualized protocol, intramuscular administration places biologics directly into well-vascularized skeletal muscle tissue. Unlike intravenous cells that experience pulmonary first-pass trapping, intramuscularly administered cells and vesicles achieve prolonged local tissue retention — acting as a sustained paracrine depot while directly supporting insulin receptor signaling in skeletal muscle, the body's primary site of glucose disposal.
Role in your protocolSelected by our medical team when sustained peripheral paracrine release and local skeletal-muscle metabolic support are clinically indicated.
Our medical team reviews your diabetes type, fasting and stimulated C-peptide levels, HbA1c history, and kidney and vascular labs to personalize cell and exosome dosages, coordinate timing safely around your daily glucose management, and structure 1, 3, and 6-month follow-up.
Role in your protocolAll adjustments to insulin or oral diabetes medications after treatment are made exclusively with your home endocrinologist based on objective glucose and HbA1c monitoring.
What we aim to achieve
How biological repair signaling connects to your metabolic goals
We establish a clear laboratory and clinical baseline before treatment in Istanbul and track your progress through structured check-ins at 1, 3, and 6 months alongside your home endocrinologist.
01
HbA1c trajectory & daily glycemic stability
By reducing systemic M1 macrophage inflammation and supporting intracellular insulin receptor signaling in muscle and liver tissues, the protocol aims to help smooth out daily glucose swings and support better long-term glycemic control. We review serial HbA1c lab results, fasting and post-meal glucose logs, and continuous glucose monitoring (CGM) time-in-range trends at 1, 3, and 6 months.
Calming islet inflammation and delivering trophic factors (IGF-1, HGF, VEGF) to the pancreatic microvasculature aims to protect surviving beta cells and support endogenous insulin secretion. Follow-up tracks fasting or stimulated C-peptide levels alongside any gradual, endocrinologist-directed adjustments to daily insulin or oral medication requirements.
Pro-angiogenic and anti-inflammatory signaling from WJ-MSCs and exosomes supports endothelial repair across small blood vessels supplying peripheral nerves and kidneys. Over the months following treatment, we monitor patient-reported changes in neuropathic tingling or burning, lower-limb circulation comfort, physical stamina, and daily recovery.
04
Procedure safety & coordinated 1, 3, and 6-month follow-up
Our medical team monitors your blood glucose and vital signs throughout your stay in Istanbul while maintaining your regular diabetes regimen safely. Structured remote reviews at 1, 3, and 6 months help you and your endocrinologist evaluate your laboratory and clinical progress.
How treatment is personalized
How our medical team evaluates your diabetes case
When you contact us, we request your diabetes history, recent lab panels, and medication schedule. Uzm. Dr. Cihan Bolat and our medical team evaluate your records, design an individualized Wharton's jelly MSC and exosome protocol where clinically appropriate, and explain the administration routes, intended therapeutic objectives, and costs before you arrange travel to Istanbul.
Medical history & reports we request
Endocrinology summary detailing diabetes type (Type 1, Type 2, or LADA), age at onset, and clinical history
Recent laboratory results including HbA1c, fasting glucose, and fasting or stimulated C-peptide levels
Current insulin regimen or oral/injectable glucose-lowering medications and recent glucose logs
Kidney function panel (creatinine, eGFR, urine albumin-to-creatinine ratio), liver panel, lipid profile, and CBC
Summary of any microvascular or cardiovascular history (neuropathy, retinopathy, or cardiac history)
Clinical suitability & timing checks
Acute diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state, or acute severe hypoglycemia requiring emergency stabilization
Active systemic infection, untreated foot ulcer infection, or acute febrile illness
Unstable cardiovascular disease or acute organ decompensation that makes international travel unsafe
Any expectation of stopping prescribed insulin abruptly without objective monitoring and endocrinologist supervision
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Diabetes stem cell therapy cost in Istanbul
Once our medical team evaluates your lab reports and medical history, we provide a clear, itemized treatment proposal detailing the recommended Wharton's jelly MSC and exosome dosages, intravenous and intramuscular administration routes, clinical monitoring, and airport and hotel support in Istanbul.
Our 2026 MSC and exosome program planning range starts from $7,000–$18,000 depending on cell dosage, exosome concentration, and selected administration routes, confirmed after your free medical evaluation.
Total Wharton's jelly MSC cell count and MSC-derived exosome dosage tailored to your metabolic profile
Combination of intravenous WJ-MSC infusion, intravenous exosomes, and intramuscular administration where included
Number of administration sessions, clinical monitoring, and stay duration in Istanbul
GMP laboratory quality certificates, VIP airport/hotel transfers, and structured 1, 3, and 6-month follow-up
How Wharton's jelly MSCs and exosomes differ between Type 1 autoimmune modulation and Type 2 insulin-resistance and beta-cell support.
02
Which combination of intravenous WJ-MSCs, intravenous exosomes, and intramuscular administration is included in my proposed protocol.
03
How my current insulin or glucose-lowering medications are maintained safely during my stay in Istanbul.
04
My exact itemized treatment cost, expected 3–5 day stay in Istanbul, and 1, 3, and 6-month lab follow-up plan.
Evidence & important considerations
Clinical evidence and important scientific context
Clinical research in diabetes includes both surgical portal-vein islet replacement for severe Type 1 diabetes and intravenous mesenchymal stromal cell trials for metabolic and immunomodulatory support. We review published evidence transparently so patients understand how our clinic's non-surgical WJ-MSC and exosome protocols work, and why clinical outcomes vary between individuals.
Two nonrandomized single-arm studies, 30 adults with type 1 diabetes and hypoglycemia unawareness
Finding
Evaluated intraportal infusion of deceased-donor islets with lifelong immunosuppression in brittle Type 1 diabetes, achieving insulin independence in a subset of recipients.
Limitation
Involved surgical portal-vein donor islet transplantation and chronic immunosuppression, which is entirely distinct from our non-surgical WJ-MSC and exosome protocols.
Small single-arm study with 14 participants followed at least 12 months, including 12 full-dose recipients
Finding
Investigated portal-vein infusion of manufactured pluripotent-derived islet cells alongside chronic immunosuppression in severe Type 1 diabetes.
Limitation
Experimental islet-replacement procedure requiring lifelong immunosuppression; does not represent intravenous or intramuscular MSC and exosome therapy.
Demonstrated good infusion tolerability, with 20% of UC-MSC recipients versus 4.55% of placebo recipients achieving the combined HbA1c <7.0% and ≥50% daily insulin reduction endpoint at 48 weeks.
Limitation
Shows supportive metabolic and insulin-sparing potential in Type 2 diabetes while confirming that responses vary between individuals and do not replace medical diabetes management.
Depending on your individualized protocol, our medical team uses GMP-certified Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes, administered via intravenous infusion and, where included in your protocol, intramuscular administration for sustained local paracrine release.
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.
